News
-
Bayer HealthCare and Meda Pharmaceuticals have filed a patent infringement suit against Apotex after Apotex submitted an ANDA for a generic version of Astepro Allergy azelastine hydrochloride nasal spray, 0.15%. The FDA approved Bayer’s NDA… Read more . . .
-
According to Liquidia Corporation, an inter partes review by the US Patent Trial and Appeal Board (PTAB) regarding US Patent No. 9,604,901, which is listed in the Orange Book as one of 7 patents covering United Therapeutics’… Read more . . .
-
Glenmark Pharmaceuticals has announced the launch of its version of Spiriva Handihaler tiotropium bromide DPI in Spain, where it will be known as Tavulus. In August 2018, Glenmark announced that it had acquired the rights… Read more . . .
-
Inhalon Biopharma and Celltrion have initiated a Phase 1 study of IN-006 inhaled regdanvimab, Inhalon said. The study is funded in part by a US Army contract worth $7 million. In July 2021, Inhalon and… Read more . . .
-
Pulmodyne and Alcove Manufacturing and Distribution have announced a new partnership for manufacturing and distribution of Alcove’s EZ-Spray intranasal mucosal atomization device and said that Pulmodyne is set to begin manufacturing and distributing EZ-Spray devices… Read more . . .
-
The American Academy of Pediatrics (AAP) has issued a clinical report highlighting serious adverse events related to off-label use of OTC oxymetazoline nasal spray in children before and after surgery, noting that in these situations… Read more . . .
-
According to Revelation Biosciences, the company has received clearance from an ethics committee for an Australian Phase 1b allergen challenge study of its REVTx-99 intranasal phosphorylated hexaacylated disaccharide (PHAD) for the treatment of allergic rhinitis… Read more . . .
-
Oncotelic Therapeutics (formerly Mateon Therapeutics) announced that it has licensed an intranasal apomorphine formulation from Autotelic, Inc, a newly formed company owned largely by Oncotelic Chairman and CEO, Vuong Trieu. Oncotelic says that it plans… Read more . . .
-
MannKind Corporation has announced the initiation of the INHALE-1 study of its Afrezza insulin DPI in type 1 and type 2 diabetes patients aged 4-17. The initial 26-week trial will evaluate Afrezza plus basal insulin versus… Read more . . .
-
Glenmark Pharmaceuticals said that its Ryaltris olopatadine / mometasone furoate nasal spray for the treatment of seasonal and perennial allergic rhinitis has received final marketing approval in 13 countries in Europe and the UK. Earlier this… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland